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List	of	abbreviations	
	
ACTH		 	 adrenocorticotropic	hormone	
AST	 	 aspartate	aminotransferase	
BSEP	 	 bile	salt	export	pump	
CEs	 	 canalicular	ectoenzymes	
CTPs	 	 canalicular	transport	proteins	
FIC1	 	 familial	intrahepatic	cholestasis	type	1	
GGT	 	 γ-glutamyltransferase	
GH	 	 growth	hormone	
HP	 	 congenital	hypopituitarism	
SOD	 	 septo-optic	dysplasia	
TSH	 	 thyroid	stimulating	hormone	
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Objective:	To	 assess	whether	 prolonged	neonatal	 cholestasis,	 described	 in	 congenital	 hypopituitarism	
(HP)	 and	 septo-optic	 dysplasia	 (SOD),	 is	 associated	 with	 altered	 expression	 of	 selected	 canalicular	
ectoenzymes	(CEs)	and	canalicular	transport	proteins	(CTPs).	
Study	 design:	Children	with	HP	 (n=21),	 SOD	 (n=18),	 and	 cholestasis	 seen	 in	 our	 centre	 over	 26	 years	
were	 reviewed.	Histopathologic	 findings	 in	 archival	 liver-biopsies	were	assessed	 (n	=	10)	 and	 in	 those	
with	 low/normal	 levels	 of	 serum	 γ-glutamyltransferase	 (GGT)	 activity	 despite	 conjugated	
hyperbilirubinaemia,	expression	of	CEs	and	CTPs	was	evaluated	immunohistochemically.		
Results:	 Patients	presented	at	 a	median	age	of	 8	weeks	 [range,	 3-20]	with	median	 total	 bilirubin	116	
μmol/L	 [45-287],	GGT	95	 IU/L	 [25-707]	and	 serum	cortisol	 51	nmol/L	 [17-240].	All	 but	3	had	 low	 free	
thyroxin	 [median	 9.6	 pmol/L	 (6.8-26.9)]	 with	 raised	 thyroid	 stimulating	 hormone	 levels	 [median	 5.95	
mU/L	(<0.1-9.24)].	Liver	histological	features	included	moderate	to	severe	intralobular	cholestasis	with	
non-specific	hepatitis,	giant-cell	transformation	of	hepatocytes	and	fibrosis.	In	all,	immunohistochemical	
staining	for	CEs	and	CTPs	revealed	a	degree	of	reduced	expression,	associated	with	normal	serum	GGT	
values	in	6	of	the	10	patients,	and	another	6	non-biopsied	cholestatic	infants	also	had	low/normal	serum	
GGT	 activity.	 	 Sequencing	 of	 ABCB11	 and	 ATP8B1	 performed	 in	 six	 of	 the	 biopsied	 patients	 did	 not	
identify	 pathogenic	 mutations.	 Following	 replacement	 therapy	 biochemical	 evidence	 of	 hepatobiliary	
injury	resolved	in	all	children	within	a	median	period	of	6	months.		
Conclusion:	Hepatobiliary	involvement	in	HP	associated	with	SOD	has	a	good	prognosis,	but	its	aetiology	
remains	uncertain.	Immunohistochemical	expression	of	CTPs	was	reduced	in	available	liver	samples.	 	
 4 
The	association	of	liver	dysfunction	with	hypopituitarism	(HP)	was	first	suggested	by	de	Mosier	in	1956	1.	
Several	 series	 of	 patients	with	 congenital	HP,	with	or	without	 septo-optic	 dysplasia	 (SOD),	 and	mixed	
(conjugated	 and	 unconjugated)	 hyperbilirubinaemia	 have	 been	 described	 2-9.	 Reported	 liver	 biopsy	
findings	 in	 these	 patients	 are	 non-specific,	 with	 intralobular	 cholestasis,	 mild	 portal	 inflammation,	
and/or	 giant-cell	 transformation	 of	 hepatocytes.	 Following	 replacement	 therapy	 with	 hydrocortisone	
and	often	thyroxin,	clinical	and	biochemical	evidence	of	hepatobiliary	injury	typically	resolves.	Failure	to	
initiate	early	 treatment	 can	exceptionally	 lead	 to	cirrhosis	and	 subsequent	 liver	 transplantation	 9.	 The	
causal	 relationship	 between	 endocrine	 abnormalities	 and	 cholestasis,	 however,	 remains	 poorly	
understood.		
Clinical	features	suggestive	of	HP	include	hypoglycaemia,	hypothermia,	ambiguous	genitalia	and	
electrolyte	 imbalance.	 “Soft”	 dysmorphic	 facial	 features	 (frontal	 bossing,	 depressed	 nasal	 bridge	 and	
saddle-shaped	 nose)	 are	 described	 9,	 10.	 	 Reported	 ocular	 abnormalities	 in	 SOD	 vary	 from	 poor	 visual	
acuity	to	complete	blindness	due	to	optic	nerve	dysplasia	or	atrophy.	Brain	defects	associated	with	SOD	
include	hypophyseal	hypoplasia	and	midline	brain	abnormalities,	such	as	absence	of	the	corpus	callosum	
and/or	septum	pellucidum	11.	
Some	of	our	cholestatic	patients	with	HP	had	serum	γ-glutamyltransferase	(GGT)	activity	levels	
either	normal	or	disproportionately	low	for	the	degree	of	conjugated	hyperbilirubinaemia	present.	The	
canalicular	 transport	 protein	 (CTP)	 bile	 salt	 export	 pump	 (BSEP)	 and	 several	 canalicular	 ectoenzymes	
(CEs)	may	be	abnormally	expressed	in	various	forms	of	intrahepatic	cholestasis	that	are	associated	with	
normal-range	 (“low”)	 GGT	 activity.	 	 We	 hypothesised	 that	 canalicular	 antigens	 might	 be	 expressed	
abnormally	in	HP.	
The	 clinical	 phenotypes	 described	 in	 the	 previous	 series,	 owing	 to	 mutation	 in	 ATP8B1	 or	
ABCB11,	vary	substantially	within	and	between	familial	intrahepatic	cholestasis	type	1	(FIC1)	deficiency	
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and	 BSEP	 deficiency.	 	 They	 range	 from	 mild,	 episodic	 cholestasis	 and	 pruritus	 (“benign”	 recurrent	
intrahepatic	cholestasis,	or	BRIC)	to	end-stage	chronic	 liver	disease	requiring	 liver	transplantation	12-15.	
Clinical	 variation	 occurs	 even	 among	patients	with	 the	 same	mutations,	 suggesting	 that	 factors	 other	
than	the	mutations	themselves	may	influence	expression	or	function	of	CEs	and	CTPs,	as	observed	with	
transient	neonatal	cholestasis	 16,	 17	or	perturbations	 in	hormonal	milieu	 (pregnancy,	oral-contraceptive	
use)	 that	 could	 precipitate	 cholestasis	 in	 previously	 asymptomatic	 individuals,	 who	 harbour	
polymorphisms	in	ATP8B1	or	ABCB11	18,	19.	
We	thought	it	was	conceivable	that	ATP8B1	or	ABCB11	variation	might	conduce	to	intrahepatic	
cholestasis	 in	 HP.	 Accordingly,	 we	 immunohistochemically	 evaluated	 CE	 and	 CTP	 expression,	 in	 the	
patients	with	HP	and	normal	(“low”)	serum	GGT	activity	despite	cholestasis.	
METHODS	
Approximately	150	infants	with	liver	disease	are	referred	annually	to	the	tertiary-care	paediatric	
liver	 centre	at	King’s	College	Hospital,	 London.	 	A	 retrospective	analysis	of	 the	patient	database	 from	
1990-2016	was	undertaken	to	identify	children	with	neonatal	cholestasis	associated	with	HP.		
Infants	 referred	 for	 investigation	 of	 prolonged	 conjugated	 jaundice	 undergo	 clinical,	
biochemical,	 and	 radiological	 evaluation,	 often	 including	 percutaneous	 liver	 biopsy.	 Initial	 endocrine	
investigations	 include	 determinations	 of	 random	 serum	 concentrations	 of	 glucose,	 cortisol,	 thyroid	
stimulating	hormone	(TSH),	and	free	thyroxin.	Children	with	random	serum	cortisol	values	<100	nmol/L	
routinely	 undergo	 short	 adrenocorticotropic	 hormone	 (ACTH;	 “Synacthen”)	 testing	 (intramuscular	
injection	of	62.5	μg	followed	by	measurement	of	cortisol	 levels	at	0,	30,	and	60	minutes)	and	detailed	
ophthalmologic	 examination	 for	 signs	 of	 SOD.	 	 If	 findings	 on	 ACTH	 testing	 are	 abnormal,	 cranial	
magnetic	 resonance	 imaging	 20	 is	performed	 to	 look	 for	anatomic	abnormalities	of	 the	pituitary	gland	
and	optic	nerves.		
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Percutaneous	liver	biopsy	is	performed	when	the	aetiology	of	cholestasis	cannot	be	established	
on	 the	 basis	 of	 non-invasive	 tests.	 	 Normal-range	 or	 “low”	 GGT	 activity	 in	 some	 infants	 prompts	
immunohistologic	study	of	expression	of	CTPs	and	CEs,	including	GGT,	in	the	liver	biopsy	material.		In	the	
present	work,	immunohistologic	evaluation	was	performed	retrospectively	(Table	1).		
Archived	 liver	 specimens	 were	 available	 from	 10	 patients.	 Tissue	 sections	 cut	 at	 4µm	 were	
stained	 with	 haematoxylin-eosin	 and,	 after	 diastase	 digestion,	 with	 periodic	 acid-Schiff	 technique.	 In	
addition,	parallel	sections	were	immunostained	(DAKO,	Chem-Mate,	Ely,	UK)	with	a	privately	generated	
rabbit	polyclonal	antibody	against	a	peptide	with	 the	sequence	of	C-terminal	BSEP	 21	and	with	mouse	
monoclonal	 antibodies	 against	 epitopes	 of	 the	 homologous	 ATP-binding	 cassette	 canalicular	
transporters	MRP2	 (Signet/Bioquote,	York,	UK;	 clone	M2III6)	and	MDR3	 (Alexis	Biochemicals	ALX-801-
028,	Nottingham,	UK)	 as	well	 as	 for	 the	 ectoenzymes	 alanyl	 aminopeptidase	 (CD13;	Novocastra	NCL-
CD13-304,	mouse	monoclonal,	 clone	 38C12;	 Vector	 Laboratories,	Newcastle-upon-Tyne,	UK)	 and	GGT	
(Abnova	 H00002678-M01,	 mouse	 monoclonal,	 clone	 1F9;	 Novus	 Biologicals,	 Cambridge,	 UK).	 All	
commercial	products	were	used	according	to	manufacturers’	instructions.	
Stored	consented	blood	samples	were	available	for	6	patients.	DNA	was	extracted	from	stored	
leucocyte-pellet	 samples	 (-80oC).	 	 Sanger	 sequencing	 was	 performed	 for	 all	 exons,	 with	 exon-intron	
junctions,	of	ABCB11	22	and	ATP8B1	20.		
RESULTS	
Twenty-one	patients	(12	male,	57%)	with	the	diagnosis	of	HP	were	identified.		All	patients	were	
born	by	spontaneous	vaginal	delivery;	all	but	2	were	born	at	term	(patients	9	and	13	at	27	and	31	weeks’	
gestation,	 respectively).	 	Median	birth	weight	was	2.2	kg	 [range,	0.975-4.3]	The	antenatal	history	was	
unremarkable	 in	 all,	 apart	 from	 patient	 13	 whose	 mother	 had	 abused	 cocaine	 and	 who	 developed	
neonatal	 abstinence	 syndrome.	 Median	 age	 at	 admission	 for	 evaluation	 of	 prolonged	 conjugated	
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jaundice	was	8	weeks	[range,	2-20].	 	Seven	(33%)	children	were	referred	during	the	first	month	of	life.	
Percutaneous	 liver	biopsy	was	performed	 in	10	children.	 	None	of	 the	patients	had	a	 family	history	of	
endocrine	disorder,	consanguinity,	or	developmental	problems.	All	other	causes	of	prolonged	neonatal	
conjugated	hyperbilirubinaemia	were	excluded.	
Clinical	findings	
	 Patients	9,	13,	and	20	had	micropenis,	and	frontal	bossing	was	evident	in	patients	9,	14,	and	18.		
Patients	 1,	 7-9,	 15,	 and	 20	 presented	 with	 recurrent	 hypoglycaemic	 episodes.	 	 Median	 serum	 total	
bilirubin	 concentration	 at	 initial	 evaluation	 in	 our	 institution	 was	 116	 µmol/L	 [range	 45-287]	 with	 a	
median	 conjugated	 fraction	 of	 83	 µmol/L	 [range	 32-165].	 	 All	 infants	 had	 transiently	 raised	 serum	
aspartate	aminotransferase	 (AST)	activity,	with	a	median	 level	of	154	 IU/L	 [range	66-445	 IU/L,	nv	<50	
IU/L].	The	median	GGT	value	was	95	 IU/L	[range	25-707	 IU/L,	nv	<55	 IU/L];	12	patients	 (57%;	Table	2)	
had	normal	serum	GGT	activity	for	age	and	sex	23.		
All	 patients	 except	 7,	 10,	 17,	 and	 21	 had	 abnormal	 random	 serum	 cortisol	 concentrations,	
median	51	nmol/L	(range,	18-240;	Table	3).		These	4	infants	with	normal	baseline	serum	cortisol	values	
had	abnormal	thyroid	function	tests	and	thus	went	on	to	undergo	ACTH	testing.		All	but	patients	4,	15,	
and	16	had	abnormal	serum	TSH	concentrations.	Twelve	of	these	patients	had	low	serum	free	thyroxin	
concentrations.		
Magnetic	resonance	imaging		assessment	of	the	pituitary	gland	and	optic	nerves	was	performed	
in	all	patients	except	5	and	12.	Among	the	19	patients	who	underwent	brain	 imaging,	all	but	2	(1,	10)	
had	pituitary	gland	abnormalities.	In	some	(n=3),	the	pituitary	stalk	was	absent,	in	some	(n=2),	the	sella	
turcica	 was	 small	 and	 the	 pituitary	 fossa	 was	 shallow,	 optic	 nerves	 were	 atrophic	 (n=11)	 and	 the	
neurohypophysis	was	small	 (n=13).	Some	patients	had	more	than	one	abnormality.	 Imaging	 in	patient	
10	 was	 normal.	 In	 patient	 1	 the	 anterior	 pituitary	 appeared	 normal,	 but	 ectopic	 pituitary	 tissue	 lay	
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dorsal	 to	 the	 optic	 chiasm.	 All	 patients	 underwent	 ophthalmologic	 examination,	 with	 dysplastic	 or	
aplastic	changes	of	the	optic	disc	diagnosed	in	11	(52%).		
The	 18	 patients,	 diagnosed	 with	 HP	 and	 hypothyroidism,	 were	 started	 on	 treatment	 with	
hydrocortisone	 (2.5	 mg	 3	 times/day)	 and	 thyroxin	 (25	 μg/day).	 Three	 patients	 with	 normal	 thyroid	
function	 were	 given	 only	 hydrocortisone	 (2.5	 mg	 3	 times/day).	 In	 the	 second	 year	 of	 life,	 growth	
hormone	(GH)	supplementation	therapy	(25	μg/kg/day)	was	started	in	14	of	the	21	patients	because	of	
poor	 linear	 growth.	 The	median	 time	 for	 serum	 AST	 and	 bilirubin	 levels	 to	 normalise	 was	 6	months	
(range,	3-9).	None	of	the	patients	had	clinical	or	ultrasonographic	signs	of	liver	disease	during	follow-up	
and	no	further	liver	biopsies	were	performed.	
The	 liver	 biopsy	 findings	 included	 moderate	 to	 severe	 degrees	 of	 cellular	 and	 canalicular	
cholestasis	 in	all	 cases,	with	prominent	multinucleated	giant	cell	 transformation	 in	most	of	 them.	The	
portal	 tracts	 were	mildly	 expanded	 due	 to	mixed	 inflammatory	 cell	 infiltrates	 and	 fibrosis,	 while	 the	
parenchyma	 had	 occasional	 haemopoietic	 foci,	 patchy	 hepatocyte	 necrosis,	 marked	 siderosis	 of	
macrophages	and	some	scattered	fatty	vacuoles.	(Table	1)	
On	 immunostaining,	 CD13	 was	 expressed	 at	 apices	 of	 cholangiocytes	 and	 along	 canalicular	
margins.	Expression	of	MRP2	was	 reduced	 in	patients	5	and	8	and	 less	widespread	 than	 that	of	CD13	
(Figure	 1).	 There	 was	 markedly	 reduced	 expression	 of	 GGT	 in	 5/7	 patients.	 Expression	 of	 BSEP	 was	
present	along	the	canaliculi	 (Figure	1),	but	 in	all	patients	 it	was	only	 focal	and	was	 less	strong	than	 in	
age-matched	controls	(Table	3).	MDR3	immunostaining	was	present	along	canalicular	margins,	although	
its	expression	was	considerably	weaker	and	less	widespread	than	that	of	MRP2	except	in	patients	5	and	
8.		Controls	marked	appropriately.	
In	view	of	the	reduced	expression	of	CTPs	and	GGT	on	immunostaining,	genetic	screening	was	
undertaken	 to	 exclude	 a	 genetic	 cause	 of	 cholestasis.	 Sanger	 sequencing	 of	 all	 exons	 of	ABCB11	 and	
 9 
ATP8B1,	 performed	 on	 patients	 1,	 3,	 4,	 7,	 8,	 and	 10,	 in	 whom	 DNA	 was	 available,	 identified	 no	
mutations.	
	
DISCUSSION	
We	note	that	57	%	of	these	cholestatic	infants	with	primary	HP	have	low	or	normal	serum	GGT.	
We	 infer	 that	 HP	 could	 underlay	 intrahepatic	 cholestasis,	 rather	 than	 simply	 co-existing	with	 it,	 from	
observed	 resolution	of	 cholestasis	with	 corticosteroid	 and	 thyroxin	 therapy.	Our	 findings	 suggest	 that	
cortisol	and	thyroxin	may	be	required	for	normal	hepatocellular	expression	of	CTPs	such	as	BSEP,	MDR3,	
and	MRP2	as	well	as	of	CEs	such	as	GGT.	
Our	series	documented	an	incidence	of	HP	in	1%	of	infants	with	conjugated	hyperbilirubinaemia	
referred	to	a	specialised	paediatric	hepatology	centre.	This	prevalence	is	lower	than	the	5%	reported	in	
general	 paediatric	 single-centre	 series	 2,	 24.	 The	 incidences	 of	 HP	 and	 SOD	 in	 the	 general	 paediatric	
population	are	reported	as	1/100,000	25	and	10.9/100,000	26,	respectively.	Infants	with	primary	adrenal	
insufficiency	 vary	 in	 severity	 of	 cholestasis,	 although	 isolated	 ACTH	 deficiency	 (secondary	
hypoadrenalism)	has	not	been	documented	in	cholestatic	patients	2,	5.		
We	have	observed	a	slight	male	prevalence	in	children	with	SOD	from	our	series,	as	eight	(73%)	
of	11	 infants	with	ocular	 involvement	were	boys,	whereas	among	the	remaining	10	only	4	(40%)	were	
male.	In	similar	series	4	of	8	patients	9	and	3	of	5	4	patients	with	SOD	were	male.		
Once	supplementation	with	hydrocortisone	and	thyroxin	was	initiated,	liver	impairment	started	
to	 improve	 in	 all	 patients	within	 the	 first	 nine	months	 of	 life.	 Spray	 et	 al.	 reported	 that	 biochemical	
indices	 of	 hepatobiliary	 injury	 normalised	 in	 7	 of	 12	 infants	 within	 6	 weeks	 of	 initiating	 such	
supplementation	9.	We	could	not	identify	any	difference	between	the	HP	children	with	and	without	SOD	
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in	respect	of	severity	of	liver	disease	or	length	of	time	required	to	clear	jaundice.		
Fourteen	 patients	 in	 our	 series	 required	 growth	 hormone	 in	 the	 second	 year	 of	 life	 when	
biochemical	 signs	 of	 liver	 dysfunction	 had	 already	 disappeared.	 This	 contrasts	 with	 findings	 in	 some	
previous	studies	11,	24,	including	an	early	report	describing	one	infant,	diagnosed	in	the	neonatal	period	
with	growth	hormone	deficiency,	who	despite	 treatment	with	hydrocortisone	had	ongoing	 liver	 injury	
on	liver	biopsy	at	age	2	years,	demonstrating	prominent	fibrosis	and	a	micronodular	distortion	of	lobular	
architecture	 5.	 It	 may	 be	 speculated	 that	 this	 infant	 had,	 in	 addition	 to	 growth	 hormone	 deficiency,	
another	underlying	liver	disorder,	not	appreciated	at	the	time.	
Histological	 signs	 of	 liver	 injury	 in	 our	 patients	 were	 relatively	 mild	 and	 non-specific	 and	
included	 hepatocellular	 and	 canalicular	 cholestasis,	 mild	 portal-tract	 inflammation,	 and	 giant-cell	
transformation	of	hepatocytes.	As	 subsequent	biopsies	were	unjustified	 in	 the	absence	of	 clinical	and	
biochemical	 signs	 of	 liver	 disease	 we	 can	 only	 speculate	 that	 the	 initial	 histological	 damage	 was	
temporary.	Minami	et	al.	have	described	a	7-year-old	girl	with	HP	and	SOD	in	whom	liver	biopsy	findings	
were	 interpreted	 as	 congenital	 hepatic	 fibrosis	 27.	 This	 may	 have	 been	 co-incidence;	 none	 of	 our	 10	
biopsied	patients	had	histological	features	of	ductal	plate	malformation	and	none	of	our	21	patients	has	
clinical	signs	of	chronic	liver	disease	or	portal	hypertension	during	follow-up.		
Some	infants	with	conjugated	hyperbilirubinaemia	have	serum	GGT	levels	that	are	either	normal	
or	 inappropriately	 low.	 	 Some	 such	 patients	 harbour	mutations	 in	ATP8B1,	 encoding	 an	 enzyme	 that	
shifts	 aminophospholipids	 from	 the	 external	 to	 the	 internal	 hemi-leaflet	 of	 the	 bile-canaliculus	
membrane	 (FIC1).	 The	 resulting	 lack	 of	 hemimembrane	 symmetry	 destabilises	 the	 membrane,	 a	
phenomenon	 associated	 with	 decreased	 expression	 of	 CEs,	 including	 GGT	 28,	 29.	 	 Without	 GGT	
expression,	 bile	 salts	 cannot	 excrete	 GGT	 into	 the	 bile,	 from	 where	 it	 refluxes	 into	 plasma	 (with	 its	
activity	measured	in	serum).	Others	have	mutations	in	ABCB11,	encoding	BSEP,	which	transfers	amino-
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acid	conjugates	of	bile	acids	from	cytoplasm	of	hepatocytes	into	the	canalicular	lumen	21.	In	this	setting	
BSEP	expression	may	be	deficient,	whilst	expression	of	other	CTPs	and	of	CEs	 is	 intact.	Consequently,	
due	to	the	 lack	of	bile	salts	GGT	cannot	be	 leached	into	bile.	The	same	holds	for	disorders	of	bile	acid	
synthesis	or	conjugation,	 in	which	substrates	suitable	 for	BSEP	are	not	produced	or	 lack	hydrophilicity	
sufficient	to	guard	against	loss	of	bile	acids	from	bile	through	canalicular	tight	junctions	30-32;	without	bile	
salts	in	the	bile,	GGT	elution	cannot	proceed	33.	Finally,	disorders	of	intracellular	trafficking	may	lead	to	
abnormal	 expression	 of	 CEs	 and	 CTPs	 alike,	 a	 setting	 in	 which	 deficiency	 in	 both	 GGT	 and	 BSEP	
expression	as	well	as	in	BSEP	function	likely	contribute	to	failure	of	serum	GGT	activity	to	increase	28,	34,	
35. The	morphological	appearances	of	the	biopsy	specimens	in	our	study	were	more	typical	of	those	seen	
in	FIC1	disease	in	the	form	of	giant	cell	hepatocyte	change.	The	morphological	appearances	in	the	biopsy	
specimens	 and	 reduction	 in	 intensity	 of	 staining	 of	 both	GGT	 and	 BSEP	 seen	 in	 this	 cohort	 suggest	 a	
combination	of	pathophysiological	mechanisms	affecting	both	expression	of	CE/CTP,	membrane	stability	
and	bile	acid	homeostasis	contributing	to	this	phenotype	rather	than	the	phenotype	being	secondary	to	
a	single	underlying	CE/CTP	defect.	
We	investigated	expression	of	CTPs	and	CEs,	 including	GGT,	 in	 the	 liver	after	observing	 low	or	
normal	serum	levels	of	GGT	activity	in	more	than	half	of	our	study	cohort	with	clinically	documented	HP.	
Indeed,	immunohistochemical	analysis	suggested	deficiency	of	hepatocellular	expression	of	some	CTPs,	
in	 particular	 BSEP.	 Transient	 intrahepatic	 cholestasis	 in	 a	 newborn	 infant	 has	 been	 reported	 in	
association	with	heterozygosity	for	a	deletion	affecting	the	ABCB11	 locus,	 identified	by	fluorescence	 in	
situ	hybridization	analysis	36.	In	our	patient	cohort,	no	ABCB11	mutations	were	found	in	the	six	patients	
analysed	(among	ten	biopsied).		
Our	observation	could	indicate	that	corticosteroid	and	thyroxin	sufficiency	is	important	for	bile	
flow	at	this	age.	Indeed,	the	histological	features	observed	in	this	series	are	reminiscent	of,	albeit	milder	
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than,	 the	 findings	 in	 the	 liver	 biopsy	 specimens	 at	 presentation	 from	 children	 with	mutation-proven	
ABCB11	disease	and	immunohistochemically	demonstrated	BSEP	deficiency.	Expression	of	CD13,	serving	
as	a	control	marker,	was	robust	 in	all	specimens,	 identifying	canaliculi	along	with	cholangiocyte	apices	
throughout	the	biopsy	material.		
Shortcomings	of	our	 study	were	 limited	number	of	 infants	who	had	 liver	biopsy,	as	often	 this	
procedure	 is	not	strongly	 indicated	 in	presence	of	confirmed	HP	and	SOD.	 In	addition,	not	all	biopsied	
patients	 had	 stored	 DNA	 for	 retrospective	 mutational	 analysis.	 Finally,	 recent	 studies	 have	 revealed	
additional	genetic	causes	of	low	GGT	cholestasis,	such	as	tight	junction	protein	2	(TJP2)	deficiency	37	and	
myosin	5B	(MYO5B)	deficiency	37,	which	were	not	tested	for	in	this	analysis	due	to	lack	of	DNA.		
A	mechanism	linking	cholestasis	with	adrenal	and	thyroid	insufficiency	in	HP	remains	uncertain.	
Isolated	 primary	 hypothyroidism	 is	 typically	 associated	 with	 unconjugated	 hyperbilirubinaemia	 38,	
suggesting	 that	 deficiency	 not	 of	 thyroid	 hormones	 but	 rather	 of	 corticosteroid	 hormones	 could	 be	
responsible	 for	 the	conjugated	 jaundice	observed	 in	primary	HP.	 In	normal	 liver,	 corticosteroids	could	
enhance	bile	output	by	increasing	the	bile-salt	independent	fraction	of	bile	flow	39,	probably	inducing	an	
increase	in	Na+/H+	exchanger	(NHE	isoform)	and	Cl-/HCO3-	exchanger	(AE2	member)	activity	resulting	in	
an	 increase	 in	 bicarbonate	 excretion	 40.	 Corticosteroids	 have	 been	 empirically	 used	 to	 improve	
cholestasis	in	a	number	of	cholestatic	conditions	41-45.	For	example,	low-dose	prednisolone	(2	mg/kg/d)	
improves	 cholestasis	 in	 younger	 infants	 with	 biliary	 atresia	 following	 hepatic	 portoenterostomy,	 but	
with	no	discernible	effect	upon	eventual	outcome	41,	46.	Whether	the	beneficial	effects	of	the	steroids	on	
cholestasis	 could	 be	 related	 to	 their	 inducing	 expression	 of	 CTPs	 or	 CEs	 at	 bile	 canaliculi	 remains	
speculative.	
Our	study	suggests	that	endocrine	mechanisms	could	be	involved	in	aberrant	expression	of	CTPs	
during	 prolonged	 neonatal	 cholestasis	 associated	 with	 primary	 HP.	 This	 observation	 may	 have	 some	
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implications	 for	 other	 cholestatic	 conditions	 and	 warrants	 further	 study	 using	 more	 sophisticated	
molecular	methods	for	assessment	of	expression	of	CTPs	in	a	larger	number	of	patients.	
	
Figure	1:	A:	Liver	biopsy	demonstrating	a	giant	cell	hepatitis	with	canalicular	cholestasis	(Patient	2,	H&E	
x200	magnification,	scale	bar	=	50	micrometers)	The	inset	shows	an	age	matched	control	with	alpha-1	
antitrypsin	deficiency,	PiZZ	(DPAS	stain	x400	magnification,	black	arrows	indicating	the	DPAS	positive	
globules	in	periportal	hepatocytes,	scale	bar	=	20	micrometers).	B:	Immunostaining	with	CD13	(Patient	
2,	main	image	x200	magnification,	scale	bar	=	50	micrometers)	demonstrated	maintained	canalicular	
CD13	expression,	comparable	with	that	seen	in	periportal	hepatocytes	in	an	age	matched	patient	with	
alpha-1	antitrypsin	deficiency	(upper	inset,	x400	magnification,	scale	bar	=	20	micrometers)	and	in	an	
age	matched	normal	control	(lower	inset	x400	magnification,	scale	bar	=	20	micrometers).	C:	MRP2	
immunostaining	(Patient	2,	MRP2,	main	image	x200	magnification,	scale	bar	=	50	micrometers)	
demonstrated	maintained	canalicular	expression,	comparable	with	that	seen	in	periportal	hepatocytes	
in	an	age	matched	alpha-1	antitrypsin	deficiency	control	(upper	inset	x400	magnification,	scale	bar	=	20	
micrometers)	and	normal	age	matched	controls	(lower	inset,	x400	magnification,	scale	bar	=	20	
micrometers).	D:	There	was	markedly	reduced	expression	of	GGT	(Patient	2	main	image	x200	
magnification,	scale	bar	=	50	micrometers)	compared	with	periportal	hepatocytes	in	an	age	matched	
alpha-1	antitrypsin	deficiency	patient	(upper	inset	x400	magnification,	scale	bar	=	20	micrometers)	and	
in	age	matched	controls	(lower	inset,	GGT	x400	magnification,	scale	bar	=	20	micrometers).	E:	Only	focal	
punctate	canalicular	expression	of	BSEP	was	seen	(Patient	2,	main	image,	BSEP	with	arrows	indicating	
BSEP	expression,	x400	magnification,	scale	bar	=	20	micrometers)	compared	with	periportal	hepatocytes	
in	an	age	matched	patient	with	alpha-1	antitrypsin	deficiency	(upper	inset	x400	magnification,	scale	bar	
=	20	micrometers)	and	age	matched	controls	(lower	inset,	BSEP	x400	magnification,	scale	bar	=	20	
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micrometers).	F:	Focal	punctate	canalicular	MDR3	expression	was	also	seen	(Patient	2,	MDR3,	main	
image,	arrows	indicate	canalicular	expression,	x400	magnification,	scale	bar	=	20	micrometers)	
compared	with	periportal	hepatocytes	in	an	age	matched	alpha-1	antitrypsin	deficiency	control	(upper	
inset,	MDR3	x400	magnification,	scale	bar	=	20	micrometers)	and	in	normal	controls	(lower	inset,	MDR3	
x	400	magnification,	scale	bar	=	20	micrometers).	
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Figure	1:	A:	Liver	biopsy	demonstrating	a	giant	cell	hepatitis	with	canalicular	cholestasis	(Patient	2,	H&E	
x200	magnification,	scale	bar	=	50	micrometers)	The	inset	shows	an	age	matched	control	with	alpha-1	
antitrypsin	deficiency,	PiZZ	(DPAS	stain	x400	magnification,	black	arrows	indicating	the	DPAS	positive	
globules	in	periportal	hepatocytes,	scale	bar	=	20	micrometers).	B:	Immunostaining	with	CD13	(Patient	
2,	main	image	x200	magnification,	scale	bar	=	50	micrometers)	demonstrated	maintained	canalicular	
CD13	expression,	comparable	with	that	seen	in	periportal	hepatocytes	in	an	age	matched	patient	with	
alpha-1	antitrypsin	deficiency	(upper	inset,	x400	magnification,	scale	bar	=	20	micrometers)	and	in	an	
age	matched	normal	control	(lower	inset	x400	magnification,	scale	bar	=	20	micrometers).	C:	MRP2	
immunostaining	(Patient	2,	MRP2,	main	image	x200	magnification,	scale	bar	=	50	micrometers)	
demonstrated	maintained	canalicular	expression,	comparable	with	that	seen	in	periportal	hepatocytes	
in	an	age	matched	alpha-1	antitrypsin	deficiency	control	(upper	inset	x400	magnification,	scale	bar	=	20	
micrometers)	and	normal	age	matched	controls	(lower	inset,	x400	magnification,	scale	bar	=	20	
micrometers).	D:	There	was	markedly	reduced	expression	of	GGT	(Patient	2	main	image	x200	
magnification,	scale	bar	=	50	micrometers)	compared	with	periportal	hepatocytes	in	an	age	matched	
alpha-1	antitrypsin	deficiency	patient	(upper	inset	x400	magnification,	scale	bar	=	20	micrometers)	and	
in	age	matched	controls	(lower	inset,	GGT	x400	magnification,	scale	bar	=	20	micrometers).	E:	Only	focal	
punctate	canalicular	expression	of	BSEP	was	seen	(Patient	2,	main	image,	BSEP	with	arrows	indicating	
BSEP	expression,	x400	magnification,	scale	bar	=	20	micrometers)	compared	with	periportal	hepatocytes	
in	an	age	matched	patient	with	alpha-1	antitrypsin	deficiency	(upper	inset	x400	magnification,	scale	bar	
=	20	micrometers)	and	age	matched	controls	(lower	inset,	BSEP	x400	magnification,	scale	bar	=	20	
micrometers).	F:	Focal	punctate	canalicular	MDR3	expression	was	also	seen	(Patient	2,	MDR3,	main	
image,	arrows	indicate	canalicular	expression,	x400	magnification,	scale	bar	=	20	micrometers)	
compared	with	periportal	hepatocytes	in	an	age	matched	alpha-1	antitrypsin	deficiency	control	(upper	
inset,	MDR3	x400	magnification,	scale	bar	=	20	micrometers)	and	in	normal	controls	(lower	inset,	MDR3	
x	400	magnification,	scale	bar	=	20	micrometers).		
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1	 +	 -	 -	 +	 +	 -	 +	 +	 -	
2	 +	 +	 -	 +	 +	 -	 +	 +	 -	
3	 +	 -	 -	 -	 n/a	 -	 +	 +	 -	
4	 +	 +	 +	 +	 _	 -	 +	 +	 -	
5	 +	 +	 -	 +	 n/a	 -	 +	 -	 +	
6	 +	 +	 -	 +	 -	 -	 +	 +	 -	
7	 +	 -	 -	 +	 n/a	 -	 +	 +	 -	
8	 +	 -	 +	 -	 +	 -	 +	 -	 +	
9	 +	 +	 +	 +	 +	 -	 +	 +	 -	
10	 +	 +	 +	 +	 +	 n/a	 +	 -	 -	
Table 1: Liver histology findings and immunostaining results from ten patients who underwent liver biopsy 
with evident cholestasis and variable expression of canalicular ectoenzymes and transport proteins. GGT; γ-
glutamyltransferase, CD13; alanyl aminopeptidase, BSEP; bile salt export pump, MRP2; multidrug resistance 
protein 2, MDR3; multidrug resistance protein 3, n/a; non available. 
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Patient Bilirubin Total 
Bilirubin 
Conjugated γ-GT AST 
 (µmol/L) (µmol/L) (IU/L) (IU/L) 
     
1 212 139 28 91 
2 139 111 137 177 
3 175 135 56 143 
4 74 47 42 91 
5 45 36 142 297 
6 100 80 282 154 
7 287 165 63 156 
8 226 127 25 201 
9 110 83 154 103 
10 213 101 38 455 
11 116 88 77 119 
12 125 115 95 342 
13 99 77 707 130 
14 75 56 85 66 
15 145 67 63 360 
16 54 32 167 93 
17 78 43 265 134 
18 167 132 234 201 
19 79 44 114 176 
20 105 48 76 83 
21 151 123 259 131 
     
Table 2: Liver biochemical profile of children presenting with conjugated hyperbilirubinaemia and subsequently 
diagnosed with congenital hypopituitarism. AST; aspartate aminotransferase, γ-GT; γ-glutamyltransferase. 
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Patient Age at 
presentation 
(weeks) 
Sex TSH 
(0.3-6 mU/L) 
Free 
Thyroxine 
(10-26 pmol/L) 
Cortisol 
(nmol/L) 
Abnormal 
Short 
ACTH 
GH 
deficiency 
MRI Head SO
D 
1 4 M 6.3 8.2 64 + + Ectopic + 
        pituitary  
2 20 F 5.6 8.3 18 + + H* - 
3 4 M 2.46 14.1 20 + + H* - 
4 6 F 4.21 12 18 + + H* + 
5 16 F <0.1 26.9 44 + + n/a - 
6 12 M 8.65 8.5 98 + - H* + 
7 3 F <0.1 9.3 240 + + H* - 
8 4 F 1.71 9.8 56 + - H* - 
9 12 M 6.59 8.0 31 + + H* + 
10 2 M 9.24 21.9 211 + - Normal + 
11 4 M <0.1 22.2 64 + + H* - 
12 8 M 7.02 9.7 <30 + + n/a - 
13 13 M 3.16 9.1 <20 + + H* + 
14 12 F 6.36 6.96 23 + - H* - 
15 7 F 2.4 24.3 86 + + H* - 
16 6 M 0.79 20.1 51 + + H* + 
17 9 M 4.99 8.6 108 + - H* + 
18 15 F <0.1 16.3 67 + - H* + 
19 12 M 7.2 9.0 45 + - H* + 
20 10 M <0.1 6.8 34 + + H* - 
21 4 F 8.02 16.2 123 + + H* + 
          
Table 3: Demographic, radiological and endocrine data on patients presenting with jaundice and diagnosed with 
congenital hypopituitarism. TSH; thyrotrophic stimulating hormone, ACTH; adrenocorticotropic hormone, GH; 
growth hormone, H*; Hypopituitarism, SOD; septo-optic dysplasia, n/a; non available. 
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